| 71 | 0 | 2 |
| 下载次数 | 被引频次 | 阅读次数 |
目的评估北京等6地区91家样本医院抗肝炎病毒药临床使用是否与国内外最新版本的肝炎《防治指南》相符合,并优化治疗方案。方法随机抽取样本医院2011年~2013年的肝病患者处方信息,利用ACCESS、金额分析和循证分析对这些信息进行统计、处理和分析。结果样本地区抗肝炎病毒药的消耗金额逐年上升;治疗模式以单药治疗为主。结论北京等6地区抗肝炎病毒药的临床用药趋势与近年公布肝炎的《防治指南》相吻合,抗肝炎病毒药物的年消费金额与用药频度同步性良好。
Abstract：[1]Thomson BJ,Finch RG.Hepatitis C virus infection[J].Clin Microbio l Infect,2005,11(2):86-94.
[2]Chen CY,Ni YH,Chen HL,et al.Lamivudine treatment in infantile fulminant hepatitis B[J].Pediatr Int,2010,52(4):672-674.
[3]Shin SR,Koh KC,Gwak GY,et al.A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudineresisitant chronic hepatitis B[J].Gut Liver,2010,4(4):530-536.
[4]Gan P,Peng F.Progress in the treatment of hepatitis B[J].Med Review,2010,16(5):720-721.
[5]Zhang CH,Wang HY.Progress research of adefovir dipivoxil[J].Hebei Medl J,2006,28(5):415-416.
[6]Zhu JD,Ma KF,Xu ZY,et al.Research progress of adefovir dipivoxil treatment in chronic hepatitis B[J].Herald Med,2010,29(10):1318-1320.
[7]Lampertico P,Vigano M,Manenti E,et al.Low resistance to adefovir combined with lamivudine:a 3-year study of 145 lamivudine-resistant hepatitis B patients[J].Gastroenterology,2007,133(5):1445-1451.
[8]Rapti I,Dimou E,Mitsoula P,et al.Adding-on versus switching-to adefovir therapy in lamivudine-resistant.HBeA g-negative chronic hepatitis B[J].Hepatology,2007,45(2):307-313.
[9]Liu CY,Xie ZY,Qin L.Rare adverse reactions of Telbivudine:transverse lines rhabdomyolysis[J].Dr ug Adverse Reactions Magaz,2009(3):201-203.
[10]Yu HQ.Telbivudine induced rhabdomyolysis in 1 patients[J].J Chin Clin Pharm,2010,19(1):57.
基本信息:
DOI：10.15912/j.cnki.gocm.2015.25.061
中图分类号:R512.6
引用信息:
[1]黄鑫,冯胜民.抗病毒性肝炎药物处方的趋势研究[J].中国医药指南,2015,13(25):92-93.DOI:10.15912/j.cnki.gocm.2015.25.061.
2015-09-10
2015-09-10